Un-Audited Financial Results of the Company for the Quarter and Nine Months Ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong Q3 FY26 results with standalone net sales of Rs. 15,992.63 lakhs, up about 57% from Rs. 10,184.09 lakhs in Q3 FY25. Profit after tax nearly doubled to Rs. 1,047.81 lakhs versus Rs. 533.26 lakhs a year ago, translating to an EPS of Rs. 22.19 (vs Rs. 11.29). For the nine months ended December 2025, revenue rose to Rs. 42,291.45 lakhs (~48% growth) and PAT climbed to Rs. 2,697.62 lakhs (~96% growth). Consolidated numbers are broadly in line with standalone, as subsidiaries contribute little. A notable concern is finance costs, which more than doubled to Rs. 1,054.95 lakhs in Q3 from Rs. 500.47 lakhs last year, suggesting higher debt or interest burden.
Strong top-line and profit growth signals healthy operating momentum and is likely positive for the stock. However, the sharp jump in finance costs is a red flag that warrants scrutiny of the company's debt levels and interest expense trajectory.